

























































A Novel Prodrug of a nNOS Inhibitor with Improved
Pharmacokinetic Potential
Cristina Maccallini,[a] Lisa Marinelli,[a] Patrick Indorf,[b] Ivana Cacciatore,[a]
Marialuigia Fantacuzzi,[a] Bernd Clement,*[b] Antonio Di Stefano,[a] and Rosa Amoroso*[a]
Under different pathological conditions, aberrant induction of
neuronal nitric oxide synthase (nNOS) generates overproduc-
tion of NO that can cause irreversible cell damage. The aim of
this study was to develop an amidoxime prodrug of a potent
nNOS inhibitor, the benzhydryl acetamidine. We synthesized
the benzhydryl acetamidoxime, which was evaluated in vitro to
ascertain the potential NOS inhibitory activity, as well as
conducting bioconversion into the parent acetamidine. The
prodrug was also profiled for in vitro physicochemical proper-
ties, by determining the lipophilicity, passive permeation
through the human gastrointestinal tract and across the blood-
brain barrier by PAMPA, and chemical, enzymatic, and plasma
stability. The obtained data demonstrate that the amidoxime
prodrug shows an improved pharmacokinetic profile with
respect to the acetamidine nNOS inhibitor, thus suggesting that
it could be a promising lead compound to treat all those
pathological conditions in which nNOS activity is dysregulated.
Introduction
Nitric oxide (NO) is a highly reactive free radical with a short
half-life, that acts as endogenous mediator.[1] Indeed, it freely
diffuses through cell membranes, interacting with the soluble
guanylyl cyclase (sGS) to regulate blood vessel vasodilatation,
as well as with many other cellular targets and pathways,
through the generation of a wide pattern of nitrosylated and
nitrosated proteins. Basically, low and regulated NO levels
ensure a multiplicity of physiological actions in the human
body, mainly in the cardiovascular system, in both the central
and peripheral nervous systems, and in the immune system. On
the other hand, when inappropriate and excessive NO produc-
tion occurs, NO takes on a pathological role, being associated
with the development of different diseases, such as neuro-
logical and inflammatory diseases, atherosclerosis, pain and
cancer.[2–4] NO is generated as a product of the enzymatic
oxidation of l-Arg to l-Cit, by the heme-containing enzyme
nitric oxide synthase (NOS).[5] There are three distinct isoforms
of NOS: the endothelial NOS (eNOS) and neuronal NOS (nNOS)
are constitutive and calcium dependent„ and catalyze the
production of low and pulsating NO levels. Then, there is the
calcium independent hinducible NOS (iNOS), which is respon-
sible for the biosynthesis of high and continuous NO levels.
eNOS is mainly expressed in endothelial cells, and plays a
pivotal role in the control of blood pressure, platelet aggrega-
tion, atherosclerosis and angiogenesis.[6,7] nNOS is localized in
neurons, in epithelial cells of various organs, and in the skeletal
muscle. This isozyme has a role in the regulation of neuro-
transmission, synaptic plasticity, and neural development as
well as in the relaxation of nonvascular smooth muscle, and in
the cardiovascular function.[8] Unlike the other two isoforms, the
expression of iNOS can be induced in different cell types in
response to pro-inflammatory stimuli, such as cytokines,
bacterial lipopolysaccharides or other inflammatory agents.[9]
Therefore, the NO generated by iNOS is strongly involved in the
defense of the organism from pathogens, and in the inflamma-
tory response.[10,11]
In mammalian cells, aberrant nNOS induction can have
detrimental consequences linked to the overproduction of NO,
generating peroxynitrite and nitrosothiols; these highly reactive
species can cause irreversible cell damage in excitotoxicity,
ischemia, Parkinson’s disease, Alzheimer’s disease and
depression.[12,13] Also iNOS induction can cause inflammatory
and autoimmune diseases, including septic shock, rheumatoid
arthritis, diabetes, multiple sclerosis, and cancer.[14,15] The
possibility of treating pathological conditions by selective
inhibition of nNOS and iNOS could represent a feasible
therapeutic strategy, and has stimulated an intense research
effort.[16,17] On the contrary, NO produced by eNOS has mainly a
physiological role, especially in maintaining vascular tone, and
its inhibition should be avoided. Several selective nNOS and/or
iNOS inhibitors have been published to date, most of them
targeting the l-Arg binding site of the enzyme oxygenase
domain, which is highly conserved among the NOS
isoforms.[18–21]
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In our continuous effort to develop selective NOS inhibitors,
we have identified several acetamidines structurally related to
1400 W, a potent inhibitor of the human iNOS (Figure 1),[22–30]
which, however, has never passed clinical trials. In particular, we
disclosed the 1-(benzhydrylamino)ethaniminium bromide (com-
pound 1) showing high potency toward nNOS and selectivity
with respect to the eNOS and iNOS (nNOS IC50=0.3 μM; eNOS/
nNOS selectivity=1166 folds; iNOS/nNOS selectivity=100
folds).[31] In this molecule the acetamidine moiety is linked to
the bulky benzhydryl group, which is responsible for the
observed selectivity. Indeed, by means of a docking study, it
emerged that compound 1 is unable to fit the iNOS binding
cavity, because it is smaller than the nNOS one. On the other
hand, it can establish favorable lipophilic interactions within the
nNOS, without steric clashes.
Generally, compounds containing an amidino group show
high basicity, resulting in low membrane penetration and poor
oral absorption. In order to overcome this restriction, the
conversion of the amidine moiety into the amidoxime (N-
hydroxyamidine) one is a developed strategy to obtain
prodrugs of antimalarials, antibacterials, thrombin inhibitors,
and antivirals.[32–35] In fact, the amidoxime has an electro-
negative oxygen atom, which makes it less basic and uncharged
at physiological pH with respect to the amidine; consequently,
the gastrointestinal (GI) absorption rate and bioavailability are
significantly improved. Once absorbed, the amidoxime pro-
drugs are converted into the corresponding active amidines by
means of the mitochondrial amidoxime reducing component
(mARC), a molybdenum-containing enzyme first identified in
2006.[36,37] In concert with the electron-transport proteins
cytochrome b5 type B (B5) and NAD(P)H-dependent cyto-
chrome b5 reductase 3 (B5R), mARC catalyzes the reduction of
several N-oxygenated compounds, like N-hydroxyguanidines,
(sulf-)hydroxamic acids, hydroxylamines and N-oxides. There are
two coding genes: MARC1 and MARC2, which have a high
sequence homology to each other. The endogenous function
and physiological role of mARC is still not fully elucidated. All
studies performed so far have underlined its role in detoxifica-
tion of mutagenic and toxic aromatic hydroxylamines and
hydroxamic acids.
In order to optimize the pharmacokinetic properties of the
nNOS inhibitor 1, in this study we present the synthesis of
amidoxime prodrug 2 (Figure 1), which was in vitro evaluated to
ascertain the potential NOS inhibitory activity, as well as its
bioconversion into the acetamidine 1 by mARC.[38] Compound 2
was also profiled for in vitro physicochemical properties, by
determining lipophilicity, passive permeation through the
human GI tract and blood–brain barrier (BBB) by a parallel
artificial membrane permeability assay (PAMPA), and chemical,
enzymatic, and plasma stability.
Results and Discussion
Chemistry
The benzyhydryl acetamidine (1) and the benzhydryl acetami-
doxime (2) were synthesized according to Scheme 1. Differently
from the previously adopted procedure,[31] compound 1 was
obtained from the solvent-free reaction of benzhydryl amine
and ethyl acetimidate hydrobromide, after 24 h under magnetic
stirring at 90 °C. Interestingly, the reaction yield was improved
with respect to the published synthesis, from 60 to 75%; also
the purification was easier, consisting in a crystallization from
water. Similarly, compound 2 was obtained in high purity from
the solvent-free reaction of benzhydryl amine and ethyl
acetohydroxamate, after 30 h of magnetic stirring at 120 °C.
Evaluation of NOS inhibition
The amidoxime 2 was evaluated for its in vitro NOS inhibitory
activity, by measuring the conversion of l-Arg to l-Cit, using a
validated HPLC method with fluorescence detection, as pre-
viously reported.[39–41] The human nNOS and iNOS inhibition
percent were calculated at 1 μM, while bovine eNOS inhibition
was evaluated at 10 μM in order to have an assessment of
compound selectivity toward eNOS. Considering the highly
conserved primary sequence (>90%) between the human and
bovine eNOS, this latter extremely resembles the human
isozyme. In particular, there is only one amino acid variation in
a hydrophobic pocket that is on the outside of the heme active
site. Therefore the different source of eNOS is usually well
accepted and should not affect the inhibitor evaluation.[42] As
previously reported, the amidine 1 displayed a good inhibitory
potency against nNOS (IC50=0.3 μM), and selectivity over iNOS
and especially eNOS (1166 folds). Since the NOS inhibition by
amidine-derivatives is strongly related to their basicity and to
the interaction with a conserved l-Glu into the catalytic site, the
amidoxime 2, designed to overcome the high basicity and the
permanent positive charge of the amidine 1, was expected to
Figure 1. Chemical structures of the iNOS inhibitor 1400 W, nNOS inhibitor 1
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possess only moderate NOS inhibitory activity. This assumption
was verified by the NOS in vitro test, which revealed that
compound 2 was able to partially inhibit nNOS at 1 μM, giving
the 53% of enzymatic inhibition. This result can be explained
considering that the hydroxyl-group could be able to give the
typical hydrogen bonding into the NOS catalytic site, like
amidine-based inhibitors do, resulting in the enzyme blocking.
On the contrary, compound 2 was not able to inhibit the eNOS
nor the inducible one, in line with the selectivity of the parent
compound 1.
Bioconversion studies
The turnover rate of the amidoxime 2 was tested by an
enzymatic NADH assay[38] with the mARC enzyme system in
comparison to the model substrate benzamidoxime (BAO). The
turnover rate for the amidoxime 2 and BAO are clearly identical
for mARC1 and very similar for mARC2. The control experiment
with B5 and B5R shows no conversion to the amidine 1
(Figure 2), as expected. These results were confirmed by an LC-
MS experiment.
The reduced amidine 1 could be found in the mARC1 and
the mARC2 incubation but not in the control experiment
(Figure 3). BAO is an excellent substrate for mARC, which is
completely converted to the corresponding benzamidine
in vivo. Due to this known in vivo studies and to other known
prodrugs which are activated by mARC, for example, upamostat
and ximelagatran,[38] it can be expected that the amidoxime
prodrug 2 will also be converted extensively in vivo, and is thus
a very suitable prodrug for the amidine 1 and making it orally
available.
Evaluation of the physicochemical properties
The herein presented amidoxime 2 was designed as prodrug of
the amidine 1 to improve membrane permeability and oral
bioavailability. In this context, the deepening of the physico-
chemical properties is essential to obtain a favorable pharmaco-
logical profile. Therefore, we investigated the lipophilicity, the
passive permeation through the human GI tract through the
PAMPA assays, and the chemical and enzymatic stabilities in
simulated GI fluids and plasma. The lipophilicity has proven to
be an extremely molecular descriptor in small molecule drug
that often correlates well with the biological activity, and the n-
octanol/water partition coefficient (logP) can be used as a
predictive tool to enable rational design. In this study, the
lipophilicity of our compounds was determined by means of
the “shake-flask method” and compared to the corresponding
values calculated by the software.[43] However, for ionizable
compounds, the distribution coefficient (logD) should be used
instead of logP in the pH range where ionic species exist.[44] In
this study, logP and logD were calculated (Table 1).
Results showed that compound 1 is hydrophilic and ionized
at all pH values, and showed, as expected, low logD values,
especially at pH 1.4 and 6.5 (  0.85 and   0.31, respectively); a
positive value of logD was obtained, albeit very low (0.75), only
Figure 2. Comparison of the NADH consumption of different incubations of
the amidoxime 2 and the model substrate of mARC BAO.
Figure 3. LC-MS spectrum of incubations with mARC1, mARC2 and B5/B5R. The peak from the reduced amidine 1 appears at 4.05 min and the peak from the
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at pH 9.4. In contrast, the amidoxime 2, that is much less
ionized of amidine 1, displayed higher logD values (from   0.16
to 0.39); therefore, the logP as free amine was analyzed. Data
revealed that amidoxime 2 (logP=3.24) was more lipophilic
than acetamidine 1 (logP=2.54) in accordance with the
corresponding calculated logP (c logP) values (3.46 and 2.89 for
compound 2 and 1, respectively).
PAMPA assay is a high-throughput technique capable of
screening compounds for passive transport across the biological
barriers in absence of enzymes and transporters, was selected
to predict the membrane permeability of our compounds as it
is strongly related to the biological activity. The relative passive
transcellular diffusion of compounds, expressed as permeability
coefficient (Pe), was determined with a permeability
equation.[45] The permeabilities of 1, 2, and 1400 W were
determined at pH 5.0, 6.5, and 7.4 to mimic the physiological
conditions of the GI tract (Table 1). Data revealed that the
obtained Pe values (>1.5×10  6) for amidoxime 2 at pH 6.5 and
7.4 were found to be within acceptable range for high-
permeability compounds, suggesting a reasonable predictability
with passive absorption at level of the GI tract. On the contrary,
compound 1 and 1400 W displayed good permeability only at
pH 7.4. As the new prodrug was designed for the potential
treatment of neurodegenerative diseases, an important param-
eter is its capability to cross the BBB. So, PAMPA-BBB assay was
performed, and results showed that compound 2, possessing a
Pe value higher than 4 compared to the parent compound, may
be able to cross the BBB and reach the cerebral area hit by the
neurodegeneration process.
The effects of gastrointestinal digestion are important
parameters to be taken into consideration in the determination
of bioavailability and bioactivity of new compounds. In
particular, the luminal instability, due to the pH or enzymatic
degradation, may compromise the transmucosal transport of
the prodrug designed for permeability enhancement. Therefore,
in this study the chemical stability of compound 2 was assessed
to exclude any undesirable degradation at acid and physiolog-
ical environments. Hydrochloric acid buffer (pH 2.0) as a non-
enzymatic simulated gastric fluid (SGF), and phosphate buffer
(pH 7.4) as nonenzymatic simulated intestinal fluid (SIF) were
employed to evaluate the chemical stability. On the other hand,
to investigate the ability of amidoxime 2 to be metabolized by
enzymes present within the GI tract, its enzymatic stability was
checked in vitro at pH 1.3 and 7.4 in the presence of pepsin and
pancreatin, respectively.
Finally, the stability in human plasma was assessed. Results
showed that amidoxime 2 resulted stable both in acid,
physiological, and plasma fluids; in fact, the HPLC chromato-
grams, obtained after incubation of with the fluids in absence
or presence of enzymes, revealed no additional peaks suggest-
ing that the amidoxime 2 was not susceptible to degradation
(see Supporting Information).
Based on these results, can be deduced that the inves-
tigated compounds possessed good stability in simulated fluids
which is predictive of a significant level of protection against a
premature chemical and enzymatic degradation in the GI
environmental as well as in the plasma. At pH 7.4 they also
showed Pe values higher than 1.5×10  6 cm/s, revealing a high
permeation toward the GI barrier. Moreover, the amidoxime 2,
endowed with the best drug-like properties (higher lipophilicity
and good permeability compared to amidine 1) could be a
suitable compound with the better capability to cross the GI
tract after oral administration.
Conclusion
In conclusion, we have synthesized the benzhydryl acetamidox-
ime as prodrug of the benzhydryl acetamidine, with the aim to
reduce the basicity and improve the absorption rate and
bioavailability. The amidoxime was evaluated in vitro to ascer-
tain the potential NOS inhibitory activity, revealing only a partial
inhibition of nNOS and inactivity toward eNOS and iNOS, and
was found completely converted into the corresponding
benzamidine after incubation in mARC1 and mARC2. The
amidoxime was also profiled for in vitro physicochemical
properties, showing an amelioration of drug-like properties
(higher lipophilicity, good GI and BBB permeability, and
chemical and enzymatic stability) compared to the parent
amidine, featuring it as a suitable prodrug orally available.
Therefore, based on the obtained results, the benzhydryl
amidoxime could be a promising compound to treat all those
pathological conditions in which nNOS activity is dysregulated.
Table 1. Lipophilicity and PAMPA-GI and PAMPA BBB permeability assays.[a]
Compd Lipophilicity PAMPA-GI permeability
Pe [10  6 cms  1][b]
PAMPA-BBB
permeability
Pe [10  6 cms  1][c]
logD 1.4 logD 6.5 logD 9.4 logP c logP pH 1.4[d] pH 6.5 [d] pH 7.4[d]
1   0.85 (�0.03)   0.31 (�0.01) 0.75 (�0.04) 2.54 (�0.62) 2.89 0.57 (�0.03) 1.02 (�0.15) 1.88 (�0.16) 2.7 (�0.09) CNS�
2   0.16 (�0.01) 0.29 (�0.01) 0.39 (�0.02) 3.24 (�0.55) 3.46 0.66 (�0.04) 1.57 (�0.12) 2.03 (�0.16) 5.7 (�2.44) CNS+
1400 W   1.82 (�0.05)   1.78 (�0.06)   1.66 (�0.06)   1.66 (�0.62)   0.32 0.98 (�0.05) 1.02 (�0.08) 1.86 (�0.75) 1.49 (�0.30) CNS 
[a] Data shown are the means � SD of three independent experiments;. [b] value <1.5×10  6 cm/s, low-permeability compounds; value >1.5×10  6 cm/s,
high-permeability compounds[46]; [c] CNS+ (indicative of high BBB permeation): Pe >4.0; CNS� (discrete BBB permeation): Pe from 4.0 to 2.0; CNS 
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All chemicals were purchased from commercial sources and used
without further purification. Flash chromatography was performed
on silica gel 60 (Merck) and TLC on silica gel 60, F254. Melting
points (m.p.) were determined on a Buchi apparatus and given
uncorrected. Infrared spectra (IR) were recorded on a FTIR 1600
PerkinElmer spectrometer. NMR spectra were run at 300 MHz on a
Varian instrument; chemical shifts (δ) are reported in ppm.
Elemental analyses were carried out with an Eurovector Euro EA
3000 model analyzer and purity of all compounds was�95%. HPLC
grade water was obtained by passage through an Elga Purelab
water purification system (Elga Labwater,UK). A centrifuge EBA21
(Hettich, Germany) was used.
Synthesis of 1-[(diphenylmethyl)amino]ethaniminium
chloride (1)
Benzhydrylamine (890 mg, 4.8 mmol) and ethylacetimidate hydro-
bromide (500 mg, 4.0 mmol) were mixed and allowed to react at
90 °C under magnetic stirring, for 24 h. The obtained pale yellow oil
was then dissolved in hot water (10 mL) and the obtained solution
was stored at 4 °C, until the desired compound 1 crystallized as a
white solid (yield 75%, m.p. 278–280 °C). 1H NMR (DMSO): δ=2.26
(s, 3H, CH3), 5.60 (s, 1H, CH), 7.29–7.41 (m, 10H, Ar);
13C NMR
(DMSO): δ=19.56, 59.21, 126.16, 128.20, 128.67, 129.01, 129.41,
139.84, 164.45. Anal. calcd. for C15H17BrN2: C 59.03, H 5.61, N 9.18;
found: C 58.91, H 5.62, N 9.17.
Synthesis of
(1E)-N-(diphenylmethyl)-N’-hydroxyethanimidamide (2)
Benzhydrylamine (1600 mg, 8.73 mmol) and ethyl N-hydroxyaceti-
midate (300 mg, 2.91 mmol) were mixed and stirred at 120 °C for
30 h. The obtained yellow, viscous liquid was purified on silica gel,
with CHCl3/CH3OH (97 :3) as the mobile phase. Compound 2 was
isolated as a yellow solid (yield 54%, m.p. 112–115 °C). 1H NMR
(CD3OD): δ=1,77 (s, 3H, CH3); 5,76 (s, 1H, CH); 7,35–7,26 (m, 10H,
Ar); 13C NMR (CD3OD): δ=13.77 (CH3), 60.19 (CH); 126.84 (Car),
126.90, 127.00, 127.35, 127.60, 128.07, 128.31, 128.62, 142,93,
152,92. Anal. calcd. for C15H16N2O: C 74.97, H 6.71, N 11.66; found: C
75.04, H 6.73, N 11.64.
Biology
Recombinant human iNOS and nNOS, were purchased from Enzo
Life Sciences, Inc. (New York, USA), while bovine recombinant eNOS
was purchased from Cayman Chemicals (Ann Arbor, Michigan,
USA). HPLC analyses were performed using a Waters system
composed of a P600 model pump, a 2475 multi-fluorescence
detector, and a 7725i model sample injector (Rheodyne, Cotati, CA,
USA) equipped with a 5 μL loop. The column was a XTerra MS C8
(250×4.6 mm i.d., 5 m particle size; Waters). A column thermostat
oven module Igloo-Cil (Cil Cluzeau Info Labo, France) was used.
Chromatograms were recorded on a Fujitsu Siemens Esprimo
computer and data were processed by the Empower Pro software
(Waters). The appropriate mobile phase was prepared daily, filtered
through a 0.45 μm WTP membrane (Whatman, Maidstone, UK),
sonicated and degassed before use. Column temperature was kept
constant at 20 °C. All assays were performed in triplicate.
Enzymatic assay for evaluation of NOS inhibition
Enzymes were diluted in 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethane-
sulfonic acid (HEPES) buffer (pH 7.4) to obtain iNOS and nNOS
2.5 μg/mL stock solutions, and eNOS 300 μg/mL stock solution. To
measure iNOS activity, 10 μL of iNOS stock solution were added to
80 μL of HEPES buffer at pH 7.4, containing 0.1 mM CaCl2, 1 mM
d,l-dithiothreitol (DTT), 0.5 mg/mL bovine serum albumin (BSA),
10 μM flavin mononucleotide (FMN), 10 μM flavin adenine dinucleo-
tide (FAD), 30 μM tetrahydrobiopterin (BH4), 10 μg/mL calmodulin
(CaM) and 10 μM l-Arg. To measure eNOS and nNOS activities,
25 μL of enzyme stock solution were added to 75 μL of HEPES
buffer pH 7.4, containing 2 mM CaCl2, 1 mM DTT, 0.5 mg/mL BSA,
10 μM FMN, 10 μM FAD, 30 μM BH4, 10 μg/mL CaM and 10 μM l-
Arg. Then, 10 μL of a 10 μM (iNOS and nNOS assay) or 100 μM
(eNOS assay) solution of the test compound was added to the
enzyme assay solution, followed by pre-incubation of 15 min at
37 °C. The reaction was initiated by the addition of 10 μL of
nicotinamide adenine dinucleotide phosphate (NADPH) 7.5 mM
(iNOS) or 10 mM (eNOS and nNOS), carried out at 37 °C for 20 min,
and stopped by adding 500 μL of ice-cold CH3CN. The mixture was
brought to dryness under vacuum and eventually stored at   20 °C,
before the fluorescence derivatization. The o-phthalaldehyde-N-
acetylcysteine (OPA/NAC) reagent for fluorescence derivatization
was prepared with the molar ratios of 1 :3, reacting 5 mL of
methanolic OPA solution and 20 mL of 0.2 M borate buffer
containing 0.1 g of NAC for 90 min to final pH 9.3�0.05. The OPA/
NAC solution was stored at 4 °C and saved for no longer than seven
days. 600 μL of HPLC grade water was added to the residue of the
enzymatic assay and centrifuged at 6000 rpm, Swing-out Rotor, for
20 min. The fluorescence reaction is realized stirring 190 μL of
supernatant and 60 μL of OPA/NAC solution for 5 min.
The HPLC column was eluted at a flow rate of 0.7 mL/min with
linear gradients of buffers A (5% CH3CN in 15 mM sodium borate
with 0.1% v/v trifluoroacetic acid, pH 9.4) and B (50% CH3CN in
8 mM sodium borate with 0.1% v/v trifluoroacetic acid, pH 9.4). The
solvent gradient was 0–20% B at 0–10 min, B to 25% at 10–15 min,
then to 40% at 15–20 min and to 70% at 20–28 min. This
composition was maintained until t=35 min, before being reduced
to the initial 0% B composition. The injection volume was 5 μL. The
fluorescence intensity of the column eluate was monitored at λex=
335 nm and λem=439 nm.
Bioconversion studies
UV/Vis NADH assay
The assay was performed as previously described.[38] The proteins
were dissolved in 20 mM of 2-(N-morpholino)ethanesulfonic acid
(MES) buffer (pH 6.0) in disposable micro UV cuvettes. Each batch
contained 15 μg human mARC, 7 μg B5 and 0.16 μg B5R. The
enzymes were preincubated with the respective substrate (concen-
tration 3 mM) for 3 min at 37 °C (total volume 240 μL). This mixture
was measured as blank value and immediately mixed with 60 μL
NADH (concentration 1 mM). The kinetics were measured over a
period of 15 min at 37 °C, with absorption between 300 and
400 nm being measured at intervals of 30 sec. The measurement
was stopped when the absorption stopped changing. The measure-
ments were taken with a Varian Cary® 50 UV/Vis spectrophotometer
from Agilent, which was tempered with a Varian Cary® PCB-150
Peltier Controlled Cryobath. The samples were mixed with cold
methanol and centrifuged for 5 min at 10000 rpm, Swing-out Rotor,
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A Bruker Amazon SL Ion Trap with upstream Agilent 1260 HPLC
system was used with a Waters Xterra MS C8, 4.6×50 mm, 3.5 μm
column, with Phenomenex, Security Guard C18 precolumn 3×
4 mm. A gradient was employed with eluent A: 0.1% acetic acid
Suprapur, Merck, in Aqua Bidest, eluent B: CH3CN, Sigma Aldrich
Chromasolv for gradient HPLC. The gradient was changed from
97% A to 100% B within 10 min. The injection volume was 1 μL
and 10 μL respectively. The column temperature was 20 °C.
Software of the HPLC: Hystar 3.2 SR 2. Software to control the mass
spectrometer: Bruker Trap Control 7.0 Software to evaluate the
data: Bruker Data Analysis 4.0.
Chemical-physical properties determination
Analytical HPLC measurements were run on a Waters 600 HPLC
pump equipped with a Waters 2996 photodiode array detector, a
20 μL Rheodyne injector and a computer-integrating apparatus.
The column was a Waters Symmetry RP-C18 column (4.6×150 mm,
5 μm). The mobile phase was a mixture of TFA 0.01 M/ACN/(MeOH/
THF 90 :10) 20/52/28 and the flow rate was 0.7 mL/min. The UV
detector was set at a length of 254 nm.
LogD and logP determination
Both n-octanol and aqueous buffer (pH 1.4, 6.5 and 9.4) solutions
were saturated of each other. 2 mg of tested compound was
dissolved in 500 μL of organic phase and mixed with an equal
volume of aqueous buffer by repeated inversions of up to
200 times for 5 min and then allowed to stand for 30 min for the
phases to fully separate. Thereafter, the respective phases were
analyzed by HPLC. The c logP values were calculated using the ACD
LogP software package, version 4.55 (Advanced Chemistry Develop-
ment Inc., Toronto, Canada).
PAMPA-GI assay
A 2% solution (w/v) of egg lecithin (phosphatidyl choline >98%) in
dodecane was employed as an artificial membrane solution. Each
donor filtration plate well, carefully impregnated with 5 L of this
solution, was added of 150 μL of 500 mM test compound buffer
solutions (phosphate buffer for pH 7.4 and pH 6.5 and hydrochloric
acid buffer for pH 1.4). Subsequently, the drug-filled donor plate
was placed onto the acceptor plate prefilled with the same buffer
(300 μL) as the acceptor solution. Once replaced the plate lid, the
resulting assembled donor-acceptor plates were incubated at room
temperature for 2 h. The concentration in the acceptor and donor
solutions were determined by HPLC. The Pe was determined as
previously reported.[47]
PAMPA-BBB assay
PAMPA-BBB assays were performed following the same procedure
described above for PAMPA-GI. Briefly, an artificial membrane
consisting in a porcine polar brain lipid extract mixture (purchased
from Avantis Polar Lipids, Alabaster, AL, USA) and an incubation
time of 18 h were adopted as experimental conditions.
Chemical and enzymatic stabilities assays
The stock solutions of compounds 1, 2, and 1400 W were prepared
by dissolving 1 mg of compound in 1 mL of EtOH and then diluting
1 :10 in ultrapure water. For chemical stability, a 0.01 M
hydrochloric acid buffer (pH 1.3) and 0.01 M phosphate buffer
(pH 7.4) were used. To assess enzymatic stability, the same
hydrochloric buffer with and without pepsin (10 or 40 mg/mL) and
phosphate buffer with and without pancreatin (10 or 40 mg/mL)
were used. The reactions were initiated by adding 50 μL of test
compound stock solution to 250 μL of aqueous buffer solution, in
screw-capped vial at 37�0.5 °C, and the mixture was shaken for 2 h
at 650 rpm. To stop the enzymatic activity, 250 μL of ice cold
CH3CN containing 0.5 vol% formic acid was added. The mixture
was vortexed and centrifuged at 2 °C and 10000 rpm, Swing-out
Rotor, for 10 min, and the content of tested compound in the
supernatant was analyzed by HPLC. Experiments were run in
triplicate and the mean values of the rate constants were
calculated.
Human plasma was purchased from 3H Biomedical (Uppsala,
Sweden). For the determination of enzymatic stability in human
plasma, the reactions were initiated by adding 50 μL of compound
stock solution to 450 μL of pre-heated plasma, and incubated at
37�0.5 °C. At appropriate time intervals, 50 μL of the plasma were
taken and deproteinized by the addition of 450 μL of CH3CN. After
mixing and centrifugation for 10 min at 10000 rpm, the super-
natant (5 μL) was analyzed by HPLC, adopting the same chromato-
graphic conditions described for chemical stability evaluations.[48]
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